Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Int Immunopharmacol ; 134: 112215, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38744173

ABSTRACT

Camelid single-domain antibodies (VHH) represent a promising class of immunobiologicals for therapeutic applications due to their remarkable stability, specificity, and therapeutic potential. To enhance the effectiveness of antivenoms for snakebites, various methods have been explored to address limitations associated with serum therapy, particularly focusing on mitigating local damage and ensuring sustainable production. Our study aimed to characterize the pharmacological profile and neutralization capacity of anti-Phospholipase A2 (PLA2) monomeric VHH (Genbank accessions: KC329718). Using a post-envenoming mouse model, we used intravital microscopy to assess leukocyte influx, measured CK and LDH levels, and conducted a histopathology analysis to evaluate VHH KC329718's ability to neutralize myotoxic activity. Our findings demonstrated that VHH KC329718 exhibited heterogeneous distribution in muscle tissue. Treatment with VHH KC329718 reduced leukocyte influx caused by BthTX-I (a Lys-49 PLA2) by 28 %, as observed through intravital microscopy. When administered at a 1:10 ratio [venom or toxin:VHH (w/w)], VHH KC329718 significantly decreased myotoxicity, resulting in a 35-40 % reduction in CK levels from BthTX-I and BthTX-II (an Asp-49 PLA2) and a 60 % decrease in CK levels from B. jararacussu venom. LDH levels also showed reductions of 60%, 80%, and 60% induced by BthTX-I, BthTX-II, and B. jararacussu venom, respectively. Histological analysis confirmed the neutralization potential, displaying a significant reduction in tissue damage and inflammatory cell count in mice treated with VHH KC329718 post B. jararacussu venom inoculation. This study underscores the potential of monomeric anti-PLA2 VHH in mitigating myotoxic effects, suggesting a promising avenue for the development of new generation antivenoms to address current therapeutic limitations.


Subject(s)
Antivenins , Bothrops , Phospholipases A2 , Single-Domain Antibodies , Snake Bites , Animals , Single-Domain Antibodies/immunology , Snake Bites/drug therapy , Snake Bites/immunology , Antivenins/pharmacology , Antivenins/therapeutic use , Mice , Phospholipases A2/metabolism , Crotalid Venoms/immunology , Crotalid Venoms/toxicity , Male , Disease Models, Animal , Muscle, Skeletal/pathology , Muscle, Skeletal/drug effects , Leukocytes/drug effects , Leukocytes/immunology , Humans , Creatine Kinase/blood
2.
Viruses ; 15(4)2023 04 21.
Article in English | MEDLINE | ID: mdl-37113000

ABSTRACT

In response to the global spread of antimicrobial resistance, there is an increased demand for novel and innovative antimicrobials. Bacteriophages have been known for their potential clinical utility in lysing bacteria for almost a century. Social pressures and the concomitant introduction of antibiotics in the mid-1900s hindered the widespread adoption of these naturally occurring bactericides. Recently, however, phage therapy has re-emerged as a promising strategy for combatting antimicrobial resistance. A unique mechanism of action and cost-effective production promotes phages as an ideal solution for addressing antibiotic-resistant bacterial infections, particularly in lower- and middle-income countries. As the number of phage-related research labs worldwide continues to grow, it will be increasingly important to encourage the expansion of well-developed clinical trials, the standardization of the production and storage of phage cocktails, and the advancement of international collaboration. In this review, we discuss the history, benefits, and limitations of bacteriophage research and its current role in the setting of addressing antimicrobial resistance with a specific focus on active clinical trials and case reports of phage therapy administration.


Subject(s)
Bacterial Infections , Bacteriophages , Phage Therapy , Humans , Bacterial Infections/microbiology , Bacteria , Anti-Bacterial Agents/therapeutic use , Bacteriophages/physiology
3.
Eur J Pharm Biopharm ; 173: 141-149, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35306127

ABSTRACT

Different carrier systems have been investigated for myocardial delivery of biopharmaceuticals for heart disease. Here, we aimed to evaluate the heart retention and tissue response of liposomes intended for cardiac drug delivery. Liposomes were produced by the lipid thin film hydration method followed by sonication. Cytocompatibility tests were performed in murine L929 fibroblasts and H2c9 cardiomyocytes using the Alamar Blue assay. In vivo experiments were assessed in a model of myocardial infarction induced by isoproterenol in mice. Cardiac delivery of fluorescent liposomes (rhodamine B-labeled) with different mean sizes (165 nm, 468 nm, 1551 nm and 1954 nm) was performed by ultrasound-guided transthoracic injection. After three days, mice were euthanized for histological evaluation using optical and fluorescence microscopy. No cytotoxic lipid concentrations were determined in the range 9.3 - 120 µM for fibroblasts and cardiomyocytes exposed to liposomes. In vivo, large liposomes induced significant inflammation in myocardium compared with the control group (p < 0.0001). In contrast, heart mice injected with 468 nm-sized liposomes exhibited a lower number of inflammatory cells. Still, a greater tissue retention 72 h post-injection was found. Therefore, this study demonstrated the feasibility of the echocardiography-guided percutaneous injection to deliver liposomes successfully into the myocardium in a minimally invasive manner. In addition, these findings indicate the potential of liposomes as carriers of biopharmaceuticals for myocardial delivery, supporting the development of further research on these delivery systems for heart disease.


Subject(s)
Liposomes , Myocardial Infarction , Animals , Mice , Myocardial Infarction/drug therapy , Myocardial Infarction/pathology , Myocardium , Ultrasonography , Ultrasonography, Interventional
4.
ChemMedChem ; 16(4): 662-678, 2021 02 17.
Article in English | MEDLINE | ID: mdl-33231370

ABSTRACT

Plasmodium parasites kill 435 000 people around the world every year due to unavailable vaccines, a limited arsenal of antimalarial drugs, delayed treatment, and the reduced clinical effectiveness of current practices caused by drug resistance. Therefore, there is an urgent need to discover and develop new antiplasmodial candidates. In this work, we present a novel strategy to develop a multitarget metallic hybrid antimalarial agent with possible dual efficacy in both sexual and asexual erythrocytic stages. A hybrid of antimalarial drugs (chloroquine and primaquine) linked by gold(I) was synthesized and characterized by spectroscopic and analytical techniques. The CQPQ-gold(I) hybrid molecule affects essential parasite targets, it inhibits ß-hematin formation and interacts moderately with the DNA minor groove. Its interaction with PfTrxR was also examined in computational modeling studies. The CQPQ-gold(I) hybrid displayed an excellent in vitro antimalarial activity against the blood-stage of Plasmodium falciparum and liver-stage of Plasmodium berghei and efficacy in vivo against P. berghei, thereby demonstrating its multiple-stage antiplasmodial activity. This metallic hybrid is a promising chemotherapeutic agent that could act in the treatment, prevention, and transmission of malaria.


Subject(s)
Antimalarials/pharmacology , Chloroquine/pharmacology , Gold/pharmacology , Primaquine/pharmacology , Antimalarials/chemistry , Chloroquine/chemistry , Dose-Response Relationship, Drug , Gold/chemistry , Humans , Malaria/drug therapy , Molecular Structure , Parasitic Sensitivity Tests , Plasmodium berghei/drug effects , Plasmodium falciparum/drug effects , Primaquine/chemistry , Structure-Activity Relationship
5.
Int J Mol Sci ; 21(17)2020 Aug 24.
Article in English | MEDLINE | ID: mdl-32846867

ABSTRACT

Due to its importance in the pathogenesis of oral squamous cell carcinoma (OSCC), the Hedgehog (HH) pathway is considered a potential therapeutic target. We investigated the effects of GANT61, a GLI inhibitor, on HH gene expression, as well as on metastatic OSCC cell proliferation and death. Following culture in DMEM medium, cytotoxicity of GANT61 against different tumor and non-tumor cell types was assessed by alamarBlue assays. Cytotoxicity analysis revealed that the metastatic HSC3 cell line was the most sensitive (IC50: 36 µM) to the tested compound. The compound's effects on the expression of HH pathways components were analyzed by qPCR and Western blot; cell viability was analyzed by trypan blue assay and flow cytometry were used to investigate cell cycle phase, morphology, and death patterns in HSC3 cells. A significant reduction in mRNA levels of the GLI1 transcription factor was found after 12 h of treatment withGANT61. Protein expression levels of other HH pathway components (PTCH1, SHH, and Gli1) and HSC3 cell viability also decreased after 24 h of treatment. Cell cycle analysis and death pattern evaluations revealed significantly increased nuclear fragmentation in sub-G1 phase, as well as cell death due to apoptosis. In conclusion, the significantly reduced GLI1 gene expression seen in response to the GLI inhibitor indicates diminished downstream activation in HH pathway components. GANT61 significantly reduced cell viability in the metastatic cell line of OSCC and promoted a significant increase in nuclear fragmentation and cell death by apoptosis.


Subject(s)
Apoptosis/drug effects , Carcinoma, Squamous Cell/pathology , Mouth Neoplasms/pathology , Pyridines/pharmacology , Pyrimidines/pharmacology , Zinc Finger Protein GLI1/genetics , Adult , Apoptosis/genetics , Carcinoma, Squamous Cell/genetics , Cell Proliferation/drug effects , Cell Proliferation/genetics , Cell Survival/drug effects , Cell Survival/genetics , Cells, Cultured , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mouth Neoplasms/genetics , Neoplasm Metastasis , Zinc Finger Protein GLI1/metabolism
6.
Int J Mol Sci ; 21(10)2020 May 22.
Article in English | MEDLINE | ID: mdl-32455951

ABSTRACT

Chagas disease is an illness caused by the protozoan parasite Trypanosoma cruzi, affecting more than 7 million people in the world. Benznidazole and nifurtimox are the only drugs available for treatment and in addition to causing several side effects, are only satisfactory in the acute phase of the disease. Sirtuins are NAD+-dependent deacetylases involved in several biological processes, which have become drug target candidates in various disease settings. T. cruzi presents two sirtuins, one cytosolic (TcSir2rp1) and the latter mitochondrial (TcSir2rp3). Here, we characterized the effects of human sirtuin inhibitors against T. cruzi sirtuins as an initial approach to develop specific parasite inhibitors. We found that, of 33 compounds tested, two inhibited TcSir2rp1 (15 and 17), while other five inhibited TcSir2rp3 (8, 12, 13, 30, and 32), indicating that specific inhibitors can be devised for each one of the enzymes. Furthermore, all inhibiting compounds prevented parasite proliferation in cultured mammalian cells. When combining the most effective inhibitors with benznidazole at least two compounds, 17 and 32, demonstrated synergistic effects. Altogether, these results support the importance of exploring T. cruzi sirtuins as drug targets and provide key elements to develop specific inhibitors for these enzymes as potential targets for Chagas disease treatment.


Subject(s)
Chagas Disease/drug therapy , Nitroimidazoles/pharmacology , Sirtuins/antagonists & inhibitors , Sirtuins/metabolism , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Animals , Cell Line , Drug Synergism , Epithelial Cells/drug effects , Epithelial Cells/parasitology , Group III Histone Deacetylases/antagonists & inhibitors , Inhibitory Concentration 50 , Macaca mulatta , Molecular Docking Simulation , Phylogeny , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sirtuins/chemistry , Trypanosoma cruzi/enzymology , Trypanosoma cruzi/genetics , Trypanosoma cruzi/pathogenicity
7.
Molecules ; 24(7)2019 Apr 03.
Article in English | MEDLINE | ID: mdl-30987092

ABSTRACT

Benznidazole and nifurtimox, the only drugs available for the treatment of Chagas disease, have limited efficacy and have been associated with severe adverse side effects. Thus, there is an urgent need to find new biotargets for the identification of novel bioactive compounds against the parasite and with low toxicity. Silent information regulator 2 (Sir2) enzymes, or sirtuins, have emerged as attractive targets for the development of novel antitrypanosomatid agents. In the present work, we evaluated the inhibitory effect of natural compounds isolated from cashew nut (Anacardium occidentale, L. Anacardiaceae) against the target enzymes TcSir2rp1 and TcSir2rp3 as well as the parasite. Two derivates of cardol (1, 2), cardanol (3, 4), and anacardic acid (5, 6) were investigated. The two anacardic acids (5, 6) inhibited both TcSir2rp1 and TcSir2rp3, while the cardol compound (2) inhibited only TcSir2rp1. The most potent sirtuin inhibitor active against the parasite was the cardol compound (2), with an EC50 value of 12.25 µM, similar to that of benznidazole. Additionally, compounds (1, 4), which were inactive against the sirtuin targets, presented anti-T. cruzi effects. In conclusion, our results showed the potential of Anacardium occidentale compounds for the development of potential sirtuin inhibitors and anti-Trypanosoma cruzi agents.


Subject(s)
Anacardium/chemistry , Plant Extracts/pharmacology , Sirtuins/antagonists & inhibitors , Trypanocidal Agents/chemistry , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/enzymology , Enzyme Activation/drug effects , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Molecular Structure , Parasitic Sensitivity Tests , Plant Extracts/chemistry
8.
Chempluschem ; 84(3): 260-267, 2019 03.
Article in English | MEDLINE | ID: mdl-31950762

ABSTRACT

Canthin-6-one alkaloids, which are present in plants of the genus Simaba, are natural compounds that are capable of acting as fluorescent probes. However, the chemical composition and fluorescent properties of most species of this genus have not been analyzed. The objective of this study was to characterize the fluorescent properties of an extract of S. bahiensis and identify the chemical entities responsible for these properties. In addition, the cell-labeling properties of the fluorescent dye from A and of the isolated compounds were characterized by confocal fluorescence microscopy and flow cytometry. One quassinoid and three fluorescent alkaloids were isolated from S. bahiensis, all compounds were identified by using NMR spectroscopy and high-resolution mass spectrometry. Staining experiments and HPLC-FL analysis shown that canthin-6-one alkaloids are the main green fluorescent compounds in the analyzed dyes. All compounds evaluated showed a cytoplasmic marker with a residence time of 24 h. The present study is the first to describe the presence of canthin-6-one alkaloids in S. bahiensis, in addition to demonstrating promising cell-labeling properties of fluorescent compounds from S. bahiensis with broad emission wavelengths.


Subject(s)
Carbolines/chemistry , Fluorescent Dyes/chemistry , Indole Alkaloids/chemistry , Simaroubaceae/chemistry , Carbolines/isolation & purification , Carbolines/toxicity , Fluorescent Dyes/isolation & purification , Fluorescent Dyes/toxicity , Hep G2 Cells , Humans , Indole Alkaloids/isolation & purification , Indole Alkaloids/toxicity , Microscopy, Confocal/methods , Microscopy, Fluorescence/methods , Plant Roots/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...